NEJM:伏立康唑诱发的骨膜炎-病例报道

2019-10-10 xing.T MedSci原创

伏立康唑是一种三氟抗真菌药物;研究者认为骨膜炎的机制与氟化物对骨骼的作用有关。

患者为一名65岁的女性,因双手逐渐肿胀并弥漫性全身疼痛而到风湿科就诊,8年前她接受了肺移植。

自移植以来,患者每日接受了伏立康唑的抗真菌药物预防治疗。体检时,两只手均出现明显的关节和软组织肿胀和疼痛(如图A所示),双肩的活动范围受限制,肩膀、肘部、颈部、下背部和膝盖骨突出处时触痛。碱性磷酸酶水平为742 U/升(参考范围为34至123)。手部X光片(如图B所示)显示她的手和腕骨中有密集、不规则的结节性骨膜炎,这一发现与伏立康唑诱发的骨膜炎一致。


伏立康唑是一种三氟抗真菌药物;研究者认为骨膜炎的机制与氟化物对骨骼的作用有关。

该患者停用伏立康唑,与移植小组协商后,未开始进一步的抗真菌预防措施。在7个月的随访中,患者疼痛减轻,尽管活动范围受限和手骨肿胀仍然存在。 
 
原始出处:

Joshua Hedrick,et al.Voriconazole-Induced Periostitis.N Engl J Med 2019;https://www.nejm.org/doi/full/10.1056/NEJMicm1814565

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1650134, encodeId=32e0165013460, content=<a href='/topic/show?id=7462256860e' target=_blank style='color:#2F92EE;'>#伏立康唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25686, encryptionId=7462256860e, topicName=伏立康唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3a823964486, createdName=lancelotzzl, createdTime=Mon Apr 20 17:37:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990454, encodeId=49ad199045407, content=<a href='/topic/show?id=de1b1018458c' target=_blank style='color:#2F92EE;'>#骨膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101845, encryptionId=de1b1018458c, topicName=骨膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sat Mar 28 10:37:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373730, encodeId=16ab3e3730e1, content=那什么时候重启抗真菌感染预防呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/20/22177ca8bf2e799a7eaac5e68377f3a0.jpg, createdBy=54b92224178, createdName=MM1824, createdTime=Thu Oct 10 10:51:03 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034975, encodeId=8ae010349e5ee, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:37:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1650134, encodeId=32e0165013460, content=<a href='/topic/show?id=7462256860e' target=_blank style='color:#2F92EE;'>#伏立康唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25686, encryptionId=7462256860e, topicName=伏立康唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3a823964486, createdName=lancelotzzl, createdTime=Mon Apr 20 17:37:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990454, encodeId=49ad199045407, content=<a href='/topic/show?id=de1b1018458c' target=_blank style='color:#2F92EE;'>#骨膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101845, encryptionId=de1b1018458c, topicName=骨膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sat Mar 28 10:37:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373730, encodeId=16ab3e3730e1, content=那什么时候重启抗真菌感染预防呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/20/22177ca8bf2e799a7eaac5e68377f3a0.jpg, createdBy=54b92224178, createdName=MM1824, createdTime=Thu Oct 10 10:51:03 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034975, encodeId=8ae010349e5ee, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:37:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2020-03-28 lfcmxl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1650134, encodeId=32e0165013460, content=<a href='/topic/show?id=7462256860e' target=_blank style='color:#2F92EE;'>#伏立康唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25686, encryptionId=7462256860e, topicName=伏立康唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3a823964486, createdName=lancelotzzl, createdTime=Mon Apr 20 17:37:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990454, encodeId=49ad199045407, content=<a href='/topic/show?id=de1b1018458c' target=_blank style='color:#2F92EE;'>#骨膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101845, encryptionId=de1b1018458c, topicName=骨膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sat Mar 28 10:37:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373730, encodeId=16ab3e3730e1, content=那什么时候重启抗真菌感染预防呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/20/22177ca8bf2e799a7eaac5e68377f3a0.jpg, createdBy=54b92224178, createdName=MM1824, createdTime=Thu Oct 10 10:51:03 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034975, encodeId=8ae010349e5ee, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:37:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2019-10-10 MM1824

    那什么时候重启抗真菌感染预防呢?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1650134, encodeId=32e0165013460, content=<a href='/topic/show?id=7462256860e' target=_blank style='color:#2F92EE;'>#伏立康唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25686, encryptionId=7462256860e, topicName=伏立康唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3a823964486, createdName=lancelotzzl, createdTime=Mon Apr 20 17:37:00 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990454, encodeId=49ad199045407, content=<a href='/topic/show?id=de1b1018458c' target=_blank style='color:#2F92EE;'>#骨膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101845, encryptionId=de1b1018458c, topicName=骨膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Sat Mar 28 10:37:00 CST 2020, time=2020-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373730, encodeId=16ab3e3730e1, content=那什么时候重启抗真菌感染预防呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/20/22177ca8bf2e799a7eaac5e68377f3a0.jpg, createdBy=54b92224178, createdName=MM1824, createdTime=Thu Oct 10 10:51:03 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034975, encodeId=8ae010349e5ee, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 10 10:37:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2019-10-10 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Antimicrob Agents Ch:伏立康唑静注累积剂量对血液病患者肾功能有何影响?

2018年8月,日本学者发表在《Antimicrob Agents Chemother》的一项研究考察了伏立康唑(VRC)累积静脉剂量对血液病患者肾功能的影响。

Transpl Infect Dis:免疫功能低下者,糖皮质激素使用对伏立康唑血药浓度影响几何?

伏立康唑(VRCZ)是一种三代的三唑类抗生素,具有广谱的抗菌活性。由于非线性的药代动力学特性,VRCZ的血药浓度高度多变;此外,还受药物相互作用、肠道吸收特性、基因多态性、炎症状态、年龄和体重等多重因素的影响。2018年8月,发表在《Transpl Infect Dis》的一项研究调查了免疫功能低下患者中,糖皮质激素使用对VRCZ血药浓度的影响。

J Am Acad Dermatol:临床医生需警惕——异体造血干细胞移植后,使用伏立康唑会增加皮肤鳞状细胞癌风险

既往的研究发现:皮肤癌是实体器官移植后最常见的恶性肿瘤,其中以皮肤鳞状细胞癌(SCC)最为常见,发生率为一般人群的65倍,患者的死亡风险亦增高52倍,随着移植后生存时间的延长其发病率逐渐增加。很多因素增加器官移植患者发生皮肤癌的危险性。近来,有多个对伏立康唑的应用与肺移植患者发生SCC的相关性报道。造血干细胞移植(HCT)患者常使用伏立康唑作为真菌感染的二级预防,但很少有研究探讨伏立康唑的使用对皮

Antimicrob Agents Ch:儿童患者如何调整伏立康唑剂量?来自中国的全新数据

2018年11月,中国学者发表在《Antimicrob Agents Chemother》的一项研究,在中国的三级医疗中心考察了儿童伏立康唑的治疗药物监测(TDM)情况。结果显示,儿童患者的谷浓度个体内和个体间变异性均较高,但开展TDM的情况不容乐观。

Eur J Clin Pharmacol:伏立康唑诱发血液肿瘤患者QT延长的风险因素有哪些?

2017年9月,发表在《Eur J Clin Pharmacol》的一项由以色列科学家进行的研究,考察了伏立康唑诱发血液肿瘤患者QT延长的临床特征和风险因素。

Clin Pharmacol Ther:伏立康唑治疗成人侵袭性真菌感染 更佳剂量如何确定?

侵袭性真菌感染的发病率与病死率逐年增加,伏立康唑具有抗菌谱广、抗菌性强、临床疗效好、不良反应少等特点,已被广泛应用于临床。2018年11月,发表在《Clin Pharmacol Ther》的一项研究调查了,伏立康唑治疗成人侵袭性真菌感染的最佳剂量。